Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05104710 · ClinicalTrials.gov registry record
Intermuscular Coherence as a Biomarker for ALS
A clinical trial of Amyotrophic Lateral Sclerosis, sponsored by University of Chicago.
- Recruiting
- Registry status
- 650
- Enrollment target
- 4
- Study locations
NCT05104710: Recruiting study of Amyotrophic Lateral Sclerosis, sponsored by University of Chicago.
NCT05104710 is a study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 650 participants, below the 892-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (27% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05104710, a study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 650 participants
- Enrollment target
- 4
- Study locations
Study Summary
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of ALS patients longitudinally to determine if IMC-βγ changes with ALS disease progression and whether such changes correlate with functional and clinical scores, or survival.
Primary Outcome
Aim 1 asks if incorporation of IMC-βγ into the Awaji criteria improves the criteria's sensitivity for diagnosing ALS.
Conditions Studied
Study Locations (4)
California
- University of California Center for Clinical Research - Irvine
Florida
- University of Miami Miller School of Medicine - Miami
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University Medical Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2026-12-31 |
What NCT05104710 shows while recruiting
NCT05104710 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, below the 892-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT05104710 reports a single indexed study location in California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05104710 about?
NCT05104710 is a clinical study titled "Intermuscular Coherence as a Biomarker for ALS". The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria),...
What is the current status of trial NCT05104710?
This trial is currently recruiting. The enrollment target is 650 participants. The study started on 2021-03-31. Estimated completion is 2026-12-31.
What conditions does trial NCT05104710 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
Who is sponsoring clinical trial NCT05104710?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05104710 being conducted?
This trial has 4 study locations across California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05104710's enrollment target sits among peer trials
650 17th of 102 higher than 86 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
-
Assessing Perceptual Effects of Interactive Tasks
RECRUITING · NA
-
PREVENT ALL ALS Study
RECRUITING
-
Spinal Cord Associative Plasticity for ALS
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI